Plain-English translation of NCT05169515 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether mosunetuzumab or glofitamab — newer immunotherapy medications — work better when combined with other drugs called CC-220 and CC-99282 in people with B-cell non-Hodgkin lymphoma. Researchers want to see if these combinations are safe and how well they help shrink tumors. You would receive the medications either as injections under the skin or through an IV, depending on which treatment arm you're assigned to.
Standard treatments for B-cell lymphoma don't work for everyone, and some patients' cancer comes back even after treatment. This trial aims to find out whether combining these newer medications might offer better results for people whose cancer has stopped responding to previous therapies.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic regularly to receive your assigned medication — either injections under the skin or through an IV — along with the other study drugs. The research team will monitor you closely with blood tests and imaging scans to check how well the treatment is working and watch for any side effects. The trial involves a dose-escalation phase (to find the right dose) and an expansion phase, and you would remain in the study as long as the treatment is helping and you're tolerating it well.
AI-generated summary from trial data · Jul 17, 2026 · Not medical advice
United States